This In Vitro Diagnostics Company Is Poised to Capture Its Share of a Growing Market

In vitro diagnostics company Accelerate Diagnostics (NASDAQ: AXDX) shared the results of a multicenter study of its Accelerate PhenoTest BC Kit at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) earlier this month. The product is intended to provide rapid results for patients suspected of having bacteremia or fungemia -- both are potentially life-threatening conditions -- to improve health outcomes. The PhenoTest BC Kit demonstrated its effectiveness in significantly reducing the time to optimal therapy and to the first antibiotic intervention for treating bloodstream infections.